2-(4-morpholinoanilino)-6-cyclohexylaminopurine and Acute Myelogenous Leukemia

2-(4-morpholinoanilino)-6-cyclohexylaminopurine has been researched along with Acute Myelogenous Leukemia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Amabile, G; Bartiromo, M; Cortese, R; D'Alise, AM; Di Giorgio, FP; Iovino, M; Musacchio, A; Sessa, F; Villa, F	1

Other Studies

1 other study(ies) available for 2-(4-morpholinoanilino)-6-cyclohexylaminopurine and Acute Myelogenous Leukemia

Article	Year
Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells. Molecular cancer therapeutics, 2008, Volume: 7, Issue:5 Topics: Antineoplastic Agents; Aurora Kinase B; Aurora Kinases; Binding Sites; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; HeLa Cells; Histones; Humans; Leukemia, Myeloid, Acute; Models, Molecular; Morpholines; Phosphorylation; Polyploidy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Purines	2008

Article

Year

Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells.

Molecular cancer therapeutics, 2008, Volume: 7, Issue:5

Topics: Antineoplastic Agents; Aurora Kinase B; Aurora Kinases; Binding Sites; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; HeLa Cells; Histones; Humans; Leukemia, Myeloid, Acute; Models, Molecular; Morpholines; Phosphorylation; Polyploidy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Purines

2008